Loading...

COVID‑19 Alert: Stay home if you feel unwell. If you have a fever, cough and difficulty breathing, seek medical attention. Follow the directions of your local health authority. Source WHO

We have a lockdown, "Working from HOME" Please reach out for any queries at: help@alliedmarketresearch.com & Int'l : +1-503-894-6022, (UK) : +44-845-528-1300

Neutropenia Treatment Market by Treatment (Colony-stimulating factors, Antibiotics, Antifungals, and Antivirals), and Distribution Channel (Hospital Pharmacies , Retail Pharmacies, and Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2020–2027

A06298
Pages: 210
May 2020 | 295 Views
 
Author(s) : Onkar Sumant, Ankita Sonar and Komal Urde
Tables: 95
Charts: 40
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Neutropenia Treatment Market

Request Now !

Neutropenia Treatment Market Overview:

The global neutropenia market size was valued at $12,602.5 million in 2019, and is expected to reach $19,303.1 million by 2027, with a CAGR of 5.4% during the forecast period. 

Neutropenia is a disease in which the amount of white blood cells (neutrophils) in the blood supply is decreased, reducing the capacity of the body to combat infections. Neutropenia is defined as an absolute count of neutrophils (ANC) below 1500 per microliter (1500/microL); severe neutropenia is defined as an ANC below 500/microL. 

Get more information on this report : Request Sample Pages

The neutropenia market is expected to register a substantial growth in the future, owing to rise in incidences of cancer cases. In addition, increase in R&D efforts by companies to develop novel therapies for treatment of neutropenia is expected to boost the market growth during the forecast period. 

However, high cost of treatment of neutropenia and stringent rules and regulations for product approvals are anticipated to hamper the neutropenia treatment market growth during the forecast period. On the contrary, transitional shift from branded drugs to low cost biosimilars is expected to provide remunerative opportunities for the market players.

The neutropenia cancer market is segmented on the basis of treatment and distribution channel. By treatment, it is categorized into colony-stimulating factor, antibiotics, and antifungals. Colony-stimulating factors are secreted glycoproteins. These bind to receptor proteins on the surface of hematopoietic stem cells. The colony-stimulating factors are of two types, namely, granulocyte-colony stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF). 

Neutropenia Treatment Market
By Treatment

Your browser does not support the canvas element.

Colony-stimualting factors is projected as one of the most lucrative segments.

Get more information on this report : Request Sample Pages

On the basis of distribution channel, it is divided into hospitals pharmacies, retail pharmacies, and online pharmacies. Neutropenia treatment drugs are marketed by various sales channel such as pharmacies, within the hospitals. These medications are also offered by online providers through registered websites, which offer the ease of ordering medicines over the internet. The retail pharmacies segment is expected to dominate the global neutropenia market, owing to adequate supply of products and easy availability and accessibility of retail pharmacies. Online pharmacies are projected to generate significant revenue in the global neutropenia treatment market during the forecast period.

Neutropenia Treatment Market
By Distribution Channel

Your browser does not support the canvas element.

Hospital pharmcaies segment holds a dominant position in 2019 and online pharmacies segment will lead over the forecast period.

Get more information on this report : Request Sample Pages

The global neutropenia treatment market is segmented on the basis of region into North America (the U.S., Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, and rest of Asia-Pacific), LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA). 

North America accounted for the largest share in the global neutropenia treatment market. The neutropenia treatment market witnessed a vast growth in North America and is expected to dominate the market in the coming years. This is attributed to the increase in incidences of leukemia in the region. According to the International Agency for Research on Cancer, in 2018, 169,270 people are living with leukemia for five years and 58,876 new leukemia cases were diagnosed in North America. In addition, major key players of the market operate in North America. Further, the demand for neutropenia treatment in North America is dominated by the US. The dominance of the region is due to a rise in demand for medicinal needs for febrile neutropenia and introduction of new legislation for promotion and production of biosimilars. 

Asia-Pacific is expected to witness highest growth rate in the market throughout the forecast period. Asia possesses high potential for the growth of neutropenia treatment market, owing to leukemia cases and number of patients undergoing first-line chemotherapy treatment. 

According to the Lancet Oncology journal, globally, 58% of new cancer patients (9.8 million out of 17 million) received chemotherapy in 2018. The report estimated that the number of new cancer cases would increase to 26 million in 2040, of which 53% (15 million out of 26 million)—an estimated 5.2 million new cancer cases — are likely to undergo chemotherapy. More than one-third of the 15 million citizens needing chemotherapy in 2040 would be residing in eastern Asia (5.2 million, 35%). In comparison, 12% (1.7 million) would live in South Central Asia, 10% (1.4 million) in South East Asia, 6% (922,452). 

Global Neutropenia Treatment Market Segmentation

The global neutropenia treatment market is segmented on the basis of treatment distribution channel and region. By treatment, the market is segmented into colony-stimulating factor, antibiotics, antifungals and antivirals. By distribution channel, it is divided into hospital pharmacies, retail pharmacies and online pharmacies. Region wise, it is analyzed across North America, Asia-Pacific, Europe, and LAMEA.

Asia-Pacific is expected to witness highest growth rate in the market throughout the forecast period. Increase in incidences of leukemia will drive the overall market during the forecast period.

Segment review

On the basis of treatment, the  colony-stimulating factor segment was the largest revenue contributor in 2019, and is anticipated to continue its dominance during the forecast period, owing to presence of major players who are focused on the development of colony-stimulating factor based drugs. In addition, colony-stimulating factor is a multifunctional cytokine and an inhibitor of hematopoietic stem cell proliferation.

On the basis of distribution channel, the hospital pharmacies segment held a dominant portion in the market, accounting for about 40.6% share of the global neutropenia treatment market in 2019. 

The major companies profiled in this report include Amgen, BeyondSpring, Kyowa Kirin, Cellerant Therapeutics, Mylan N.V., Novartis AG, Partner Therapeutics, Pfizer, Spectrum Pharmaceuticals and Teva Pharmaceutical Industries Ltd. Other players in neutropenia market (not profiled in the report) include Myelo Therapeutics, and Enzychem Lifesciences Corporation Samsung Medical Center. 

Key Benefits For Stakeholders

  • The study provides an in-depth analysis of the global neutropenia market size along with the current trends and future estimations to elucidate the imminent investment pockets.

  • It offers neutropenia treatment market analysis from 2020 to 2027, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market.

  • A comprehensive analysis on region assists to understand the regional market and facilitate the strategic business planning and determine prevailing opportunities. 

  • The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global neutropenia market growth.

  • Key market players and their strategies are provided to understand the competitive outlook of the market.

Key Market Segments

By Treatment

  • Colony-stimulating factor 
  • Antibiotics 
  • Antifungals
  • Antivirals  

By Distribution channel

  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies

By Region 

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK 
    • Germany 
    • France 
    • Italy
    • Spain 
    • Rest of Europe
  • Asia-Pacific
    • Japan 
    • China
    • Australia 
    • India
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil 
    • South Africa
    • Saudi Arabia
    • Rest of LAMEA
 

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology

1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools & models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.CXO perspective

CHAPTER 3:MARKET OVERVIEW

3.1.Market definition and scope
3.2.Key findings

3.2.1.Pipeline Analysis
3.2.2.Top winning strategies
3.2.3.Top player positioning

3.3.Key forces shaping the global neutropenia treatment market
3.4.Market dynamics

3.4.1.Drivers

3.4.1.1.Rise in prevalence of leukemia
3.4.1.2.Surge in R&D efforts and development of new drugs
3.4.1.3.Fundamental shift from branded drugs to biosimilars in cancer supportive treatment

3.4.2.Restraints

3.4.2.1.High cost of the treatment of neutropenia
3.4.2.2.Stringent rules and regulations for product approvals

3.4.3.Opportunity

3.4.3.1.Robust drug pipeline for neutropenia treatment

3.5.Standard of Care for Neutropenia treatment and recommended guidelines

CHAPTER 4:GLOBAL NEUTROPENIA TREATMENT MARKET, BY TREATMENT

4.1.Overview

4.1.1.Market size and forecast

4.2.Colony-stimulating factors (CSFs) 

4.2.1.Key market trends, growth factors and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country

4.3.Antibiotics

4.3.1.Key market trends, growth factors and opportunities
4.3.2.Market size and forecast, by region
4.3.3.Market analysis, by country

4.4.Antifungals

4.4.1.Key market trends, growth factors and opportunities
4.4.2.Market size and forecast, by region
4.4.3.Market analysis, by country

4.5.Antivirals

4.5.1.Key market trends, growth factors and opportunities
4.5.2.Market size and forecast, by region
4.5.3.Market analysis, by country

CHAPTER 5:GLOBAL NEUTROPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL

5.1.Overview

5.1.1.Market size and forecast

5.2.Hospital Pharmacies

5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country

5.3.Retail Pharmacies

5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country

5.4.Online Pharmacies

5.4.1.Market size and forecast, by region
5.4.2.Market analysis, by country

CHAPTER 6:GLOBAL NEUTROPENIA TREATMENT MARKET, BY REGION

6.1.Overview

6.1.1.Market size and forecast

6.2.North America

6.2.1.Key market trends and opportunities
6.2.2.Market size and forecast, by treatment
6.2.3.Market size and forecast, by distribution channel
6.2.4.Market size and forecast, by country

6.2.4.1.U.S. 
6.2.4.2.Purchasing/distribution channels in the U.S. 

6.2.4.2.1.U.S. market size and forecast, by treatment
6.2.4.2.2.U.S. market size and forecast, by distribution channel

6.2.4.3.Canada

6.2.4.3.1.Canada market size and forecast, by treatment
6.2.4.3.2.Canada market size and forecast, by distribution channel

6.2.4.4.Mexico

6.2.4.4.1.Mexico market size and forecast, by treatment
6.2.4.4.2.Mexico market size and forecast, by distribution channel

6.3.Europe

6.3.1.Key market trends and opportunities
6.3.2.Market size and forecast, by treatment
6.3.3.Market size and forecast, by distribution channel
6.3.4.Market size and forecast, by country

6.3.4.1.Purchasing/distribution channels in the Europe
6.3.4.2.Germany

6.3.4.2.1.Germany market size and forecast, by treatment
6.3.4.2.2.Germany market size and forecast, by distribution channel

6.3.4.3.France

6.3.4.3.1.France market size and forecast, by treatment
6.3.4.3.2.France market size and forecast, by distribution channel

6.3.4.4.UK

6.3.4.4.1.UK market size and forecast, by treatment
6.3.4.4.2.UK market size and forecast, by distribution channel

6.3.4.5.Italy

6.3.4.5.1.Italy market size and forecast, by treatment
6.3.4.5.2.Italy market size and forecast, by distribution channel

6.3.4.6.Spain

6.3.4.6.1.Spain market size and forecast, by treatment
6.3.4.6.2.Spain market size and forecast, by distribution channel

6.3.4.7.Rest of Europe

6.3.4.7.1.Rest of Europe market size and forecast, by treatment
6.3.4.7.2.Rest of Europe market size and forecast, by distribution channel

6.4.Asia-Pacific

6.4.1.Key market trends and opportunities
6.4.2.Market size and forecast, by treatment
6.4.3.Market size and forecast, by distribution channel
6.4.4.Market size and forecast, by country

6.4.4.1.Japan

6.4.4.1.1.Purchasing/distribution channels in the Japan
6.4.4.1.2.Japan market size and forecast, by treatment
6.4.4.1.3.Japan market size and forecast, by distribution channel

6.4.4.2.China

6.4.4.2.1.China market size and forecast, by treatment
6.4.4.2.2.China market size and forecast, by distribution channel

6.4.4.3.Australia

6.4.4.3.1.Australia market size and forecast, by treatment
6.4.4.3.2.Australia market size and forecast, by distribution channel

6.4.4.4.India

6.4.4.4.1.India market size and forecast, by treatment
6.4.4.4.2.India market size and forecast, by distribution channel

6.4.4.5.Rest of Asia-Pacific

6.4.4.5.1.Rest of Asia-Pacific market size and forecast, by treatment
6.4.4.5.2.Rest of Asia-Pacific market size and forecast, by distribution channel

6.5.LAMEA

6.5.1.Key market trends and opportunities
6.5.2.Market size and forecast, by treatment
6.5.3.Market size and forecast, by distribution channel
6.5.4.Market size and forecast, by country

6.5.4.1.Brazil

6.5.4.1.1.Brazil market size and forecast, by treatment
6.5.4.1.2.Brazil market size and forecast, by distribution channel

6.5.4.2.Saudi Arabia

6.5.4.2.1.Saudi Arabia market size and forecast, by treatment
6.5.4.2.2.Saudi Arabia market size and forecast, by distribution channel

6.5.4.3.South Africa

6.5.4.3.1.South Africa market size and forecast, by treatment
6.5.4.3.2.South Africa market size and forecast, by distribution channel

6.5.4.4.Rest of LAMEA

6.5.4.4.1.Rest of LAMEA market size and forecast, by treatment
6.5.4.4.2.Rest of LAMEA market size and forecast, by distribution channel

CHAPTER 7:COMPANY PROFILES

7.1.AMGEN INC. 

7.1.1.Company overview
7.1.2.Company snapshot
7.1.3.Operating business segments
7.1.4.Product portfolio
7.1.5.Business performance
7.1.6.Key strategic moves and developments

7.2.BEYONDSPRING INC. 

7.2.1.Company overview
7.2.2.Company snapshot
7.2.3.Product portfolio
7.2.4.Business performance
7.2.5.Key strategic moves and developments

7.3.CELLERANT THERAPEUTICS, INC. 

7.3.1.Company overview
7.3.2.Company snapshot
7.3.3.Product portfolio
7.3.4.Key strategic moves and developments

7.4.KYOWA KIRIN

7.4.1.Company overview
7.4.2.Company snapshot
7.4.3.Operating business segments
7.4.4.Product portfolio
7.4.5.Business performance

7.5.MYLAN N.V. 

7.5.1.Company overview
7.5.2.Company snapshot
7.5.3.Operating business segments
7.5.4.Product portfolio
7.5.5.Business performance
7.5.6.Key strategic moves and developments

7.6.NOVARTIS AG

7.6.1.Company overview
7.6.2.Company snapshot
7.6.3.Operating business segments
7.6.4.Product portfolio
7.6.5.Business performance

7.7.PARTNER THERAPEUTICS, INC. 

7.7.1.Company overview
7.7.2.Company snapshot
7.7.3.Product portfolio
7.7.4.Key strategic moves and developments

7.8.PFIZER INC. 

7.8.1.Company overview
7.8.2.Company snapshot
7.8.3.Operating business segments
7.8.4.Product portfolio
7.8.5.Business performance
7.8.6.Key strategic moves and developments

7.9.SPECTRUM PHARMACEUTICALS, INC. 

7.9.1.Company overview
7.9.2.Company snapshot
7.9.3.Operating business segments
7.9.4.Product portfolio
7.9.5.Business performance

7.10.TEVA PHARMACEUTICAL INDUSTRIES LTD. 

7.10.1.Company overview
7.10.2.Company snapshot
7.10.3.Operating business segments
7.10.4.Product portfolio
7.10.5.Business performance

7.11.COHERUS BIOSCIENCES, INC. 

7.11.1.Company overview
7.11.2.Company snapshot
7.11.3.Operating business segments
7.11.4.Product portfolio
7.11.5.Business performance
7.11.6.Key strategic moves and developments

LIST OF TABLES

TABLE 01.DOSAGE AND ADMINISTRATION OF CSFS
TABLE 02.GLOBAL NEUTROPENIA TREATMENT MARKET, BY TREATMENT, 2019–2027 ($MILLION) 
TABLE 03.GLOBAL NEUTROPENIA TREATMENT MARKET FOR COLONY-STIMULATING FACTOR, BY REGION, 2019–2027($MILLION) 
TABLE 04.GLOBAL NEUTROPENIA TREATMENT MARKET FOR ANTIBIOTICS, BY REGION, 2019–2027($MILLION) 
TABLE 05.GLOBAL NEUTROPENIA TREATMENT MARKET FOR ANTIFUNGAL, BY REGION, 2019–2027($MILLION) 
TABLE 06.GLOBAL NEUTROPENIA TREATMENT MARKET FOR ANTIVIRALS, BY REGION, 2019–2027($MILLION) 
TABLE 07.GLOBAL NEUTROPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION) 
TABLE 08.GLOBAL NEUTROPENIA TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2019–2027($MILLION) 
TABLE 09.GLOBAL NEUTROPENIA TREATMENT MARKET FOR RETAIL PHARMACIES, BY REGION, 2019–2027($MILLION) 
TABLE 10.GLOBAL NEUTROPENIA TREATMENT MARKET FOR ONLINE PHARMACIES, BY REGION, 2019–2027($MILLION) 
TABLE 11.GLOBAL NEUTROPENIA TREATMENT MARKET, BY REGION 2019–2027, ($MILLION) 
TABLE 12.NORTH AMERICA NEUTROPENIA TREATMENT MARKET, BY TREATMENT, 2019-2027, ($MILLION) 
TABLE 13.NORTH AMERICA NEUTROPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION) 
TABLE 14.NORTH AMERICA NEUTROPENIA TREATMENT MARKET, BY COUNTRY, 2019-2027, ($MILLION) 
TABLE 15.U.S. NEUTROPENIA TREATMENT MARKET, BY TREATMENT, 2019-2027, ($MILLION) 
TABLE 16.U.S. NEUTROPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION) 
TABLE 17.CANADA NEUTROPENIA TREATMENT MARKET, BY TREATMENT, 2019-2027, ($MILLION)
TABLE 18.CANADA NEUTROPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION) 
TABLE 19.MEXICO NEUTROPENIA TREATMENT MARKET, BY TREATMENT, 2019-2027, ($MILLION) 
TABLE 20.MEXICO NEUTROPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION) 
TABLE 21.EUROPE NEUTROPENIA TREATMENT MARKET, BY TREATMENT, 2019-2027, ($MILLION) 
TABLE 22.EUROPE NEUTROPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION) 
TABLE 23.EUROPE NEUTROPENIA TREATMENT MARKET, BY COUNTRY, 2019-2027, ($MILLION) 
TABLE 24.GERMANY NEUTROPENIA TREATMENT MARKET, BY TREATMENT, 2019-2027, ($MILLION) 
TABLE 25.GERMANY NEUTROPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION) 
TABLE 26.FRANCE NEUTROPENIA TREATMENT MARKET, BY TREATMENT, 2019-2027, ($MILLION) 
TABLE 27.FRANCE NEUTROPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION) 
TABLE 28.UK NEUTROPENIA TREATMENT MARKET, BY TREATMENT, 2019-2027, ($MILLION) 
TABLE 29.UK NEUTROPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION) 
TABLE 30.ITALY NEUTROPENIA TREATMENT MARKET, BY TREATMETN, 2019-2027, ($MILLION) 
TABLE 31.ITALY NEUTROPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION) 
TABLE 32.SPAIN NEUTROPENIA TREATMENT MARKET, BY TREATMENT, 2019-2027, ($MILLION) 
TABLE 33.SPAIN NEUTROPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION) 
TABLE 34.REST OF EUROPE NEUTROPENIA TREATMENT MARKET, BY TREATMENT, 2019-2027, ($MILLION) 
TABLE 35.REST OF EUROPE NEUTROPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION) 
TABLE 36.ASIA-PACIFIC NEUTROPENIA TREATMENT MARKET, BY TREATMENT, 2019-2027, ($MILLION) 
TABLE 37.ASIA-PACIFIC NEUTROPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION) 
TABLE 38.ASIA-PACIFIC NEUTROPENIA TREATMENT MARKET, BY COUNTRY, 2019-2027, ($MILLION) 
TABLE 39.JAPAN NEUTROPENIA TREATMENT MARKET, BY TREATMENT, 2019-2027, ($MILLION) 
TABLE 40.JAPAN NEUTROPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION) 
TABLE 41.CHINA NEUTROPENIA TREATMENT MARKET, BY TREATMENT, 2019-2027, ($MILLION) 
TABLE 42.CHINA NEUTROPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION) 
TABLE 43.AUSTRALIA NEUTROPENIA TREATMENT MARKET, BY TREATMENT, 2019-2027, ($MILLION) 
TABLE 44.AUSTRALIA NEUTROPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION) 
TABLE 45.INDIA NEUTROPENIA TREATMENT MARKET, BY TREATMENT, 2019-2027, ($MILLION) 
TABLE 46.INDIA NEUTROPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION) 
TABLE 47.REST OF ASIA-PACIFIC NEUTROPENIA TREATMENT MARKET, BY TREATMENT, 2019-2027, ($MILLION) 
TABLE 48.REST OF ASIA-PACIFIC NEUTROPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION) 
TABLE 49.LAMEA NEUTROPENIA TREATMENT MARKET, BY TREATMENT, 2019-2027, ($MILLION) 
TABLE 50.LAMEA NEUTROPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION) 
TABLE 51.LAMEA NEUTROPENIA TREATMENT MARKET, BY COUNTRY, 2019-2027, ($MILLION) 
TABLE 52.BRAZIL NEUTROPENIA TREATMENT MARKET, BY TREATMENT, 2019-2027, ($MILLION) 
TABLE 53.BRAZIL NEUTROPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION) 
TABLE 54.SAUDI ARABIA NEUTROPENIA TREATMENT MARKET, BY TREATMENT, 2019-2027, ($MILLION) 
TABLE 55.SAUDI ARABIA NEUTROPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION) 
TABLE 56.SOUTH AFRICA NEUTROPENIA TREATMENT MARKET, BY TREATMENT, 2019-2027, ($MILLION) 
TABLE 57.SOUTH AFRICA NEUTROPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION) 
TABLE 58.REST OF LAMEA NEUTROPENIA TREATMENT MARKET, BY TREATMENT, 2019-2027, ($MILLION) 
TABLE 59.REST OF LAMEA NEUTROPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION) 
TABLE 60.AMGEN: COMPANY SNAPSHOT
TABLE 61.AMGEN: OPERATING SEGMENTS
TABLE 62.AMGEN: PRODUCT PORTFOLIO
TABLE 63.AMGEN: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 64.BEYONDSPRING : COMPANY SNAPSHOT
TABLE 65.BEYONDSPRING : PRODUCT PORTFOLIO
TABLE 66.BEYONDSPRING : KEY STRATEGIC MOVES AND DEVELOPMENT
TABLE 67.CELLERANT THERAPEUTICS : COMPANY SNAPSHOT
TABLE 68.CELLERANT THERAPEUTICS : PRODUCT PORTFOLIO
TABLE 69.CELLERANT THERAPEUTICS : KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 70.KYOWA KIRIN : COMPANY SNAPSHOT
TABLE 71.KYOWA KIRIN: OPERATING SEGMENTS
TABLE 72.KYOWA KIRIN : PRODUCT PORTFOLIO
TABLE 73.MYLAN: COMPANY SNAPSHOT
TABLE 74.MYLAN: OPERATING SEGMENTS
TABLE 75.MYLAN: PRODUCT PORTFOLIO
TABLE 76.MYLAN : KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 77.NOVARTIS: COMPANY SNAPSHOT
TABLE 78.NOVARTIS: OPERATING SEGMENTS
TABLE 79.NOVARTIS: PRODUCT PORTFOLIO
TABLE 80.PARTNER THERAPEUTICS : COMPANY SNAPSHOT
TABLE 81.PARTNER THERAPEUTICS : PRODUCT PORTFOLIO
TABLE 82.PARTNER THERAPEUTICS : KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 83.PFIZER : COMPANY SNAPSHOT
TABLE 84.PFIZER : OPERATING SEGMENTS
TABLE 85.PFIZER : PRODUCT PORTFOLIO
TABLE 86.PFIZER : KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 87.SPECTRUM PHARMACEUTICALS : COMPANY SNAPSHOT
TABLE 88.SPECTRUM PHARMACEUTICALS : OPERATING SEGMENTS
TABLE 89.SPECTRUM PHARMACEUTICALS : PRODUCT PORTFOLIO
TABLE 90.TEVA: COMPANY SNAPSHOT
TABLE 91.TEVA: OPERATING SEGMENTS
TABLE 92.TEVA: PRODUCT PORTFOLIO
TABLE 93.COHERUS BIOSCIENCES: COMPANY SNAPSHOT
TABLE 94.COHERUS BIOSCIENCES : OPERATING SEGMENTS
TABLE 95.COHERUS BIOSCIENCES: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01.SEGMENTATION OF GLOBAL NEUTROPENIA TREATMENT MARKET
FIGURE 02.PIPELINE ANALYSIS, BY COUNTRY
FIGURE 03.PIPELINE ANALYSIS, BY PHASES
FIGURE 04.PIPELINE ANALYSIS, BY YEAR
FIGURE 05.TOP WINNING STRATEGIES, BY YEAR
FIGURE 06.TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 07.TOP WINNING STRATEGIES, BY COMPANY
FIGURE 08.TOP PLAYER POSTIONING, 2019
FIGURE 09.HIGH BARGAINING POWER OF SUPPLIERS
FIGURE 10.LOW BARGAINING POWER OF BUYERS
FIGURE 11.MODERATE THREAT OF SUBSTITUTION
FIGURE 12.MODERATE THREAT OF NEW ENTRANT
FIGURE 13.MODERATE COMPETITIVE RIVALRY
FIGURE 14.GLOBAL NEUTROPENIA TREATMENT MARKET: DRIVERS, RESTRAINTS, AND OPPORTUNITIES
FIGURE 15.COMPARATIVE SHARE ANALYSIS OF NEUTROPENIA TREATMENT MARKET FOR COLONY-STIMULATING FACTOR, BY COUNTRY, 2019 & 2027 (%)
FIGURE 16.COMPARATIVE SHARE ANALYSIS OF NEUTROPENIA TREATMENT MARKET FOR ANTIBIOTICS, BY COUNTRY,  2019 & 2027 (%)
FIGURE 17.COMPARATIVE SHARE ANALYSIS OF NEUTROPENIA MARKET FOR ANTIFUNGAL, BY COUNTRY, 2019 & 2027 (%)
FIGURE 18.COMPARATIVE SHARE ANALYSIS OF NEUTROPENIA TREATMENT MARKET FOR ANTIVIRALS, BY COUNTRY,  2019 & 2027 (%)
FIGURE 19.COMPARATIVE SHARE ANALYSIS OF GLOBAL NEUTROPENIA TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2019 & 2027 (%)
FIGURE 20.COMPARATIVE SHARE ANALYSIS OF GLOBAL NEUTROPENIA TREATMENT MARKET FOR RETAIL PHARMACIES,  BY COUNTRY, 2019 & 2027 (%)
FIGURE 21.COMPARATIVE SHARE ANALYSIS OF GLOBAL NEUTROPENIA TREATMENT MARKET FOR ONLINE PHARMACIES,  BY COUNTRY, 2019 & 2027 (%)
FIGURE 22.U.S. NEUTROPENIA MARKET, 2020–2027 ($MILLION) 
FIGURE 23.AMGEN: NET SALES, 2017–2019 ($MILLION) 
FIGURE 24.AMGEN : REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 25.KYOWA KIRIN : NET SALES, 2017–2019 ($MILLION) 
FIGURE 26.KYOWA KIRIN : REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 27.KYOWA KIRIN : REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 28.MYLAN: NET SALES, 2017–2019 ($MILLION) 
FIGURE 29.MYLAN: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 30.NOVARTIS: NET SALES, 2017–2019 ($MILLION) 
FIGURE 31.NOVARTIS: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 32.NOVARTIS: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 33.PFIZER : NET SALES, 2017–2019 ($MILLION) 
FIGURE 34.PFIZER : REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 35.PFIZER: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 36.SPECTRUM PHARMACEUTICALS : NET SALES, 2016–2018 ($MILLION) 
FIGURE 37.SPECTRUM PHARMACEUTICALS: REVENUE SHARE, BY REGION, 2018 (%)
FIGURE 38.TEVA: NET SALES, 2017–2019 ($MILLION) 
FIGURE 39.TEVA: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 40.COHERUS BIOSCIENCES : NET SALES, 2017–2019 ($MILLION) 


 

 
 


Neutropenia is a condition that occurs when body does not have enough neutrophils, an important white blood cell that helps fight against infections. The treatment for neutropenia is anticipated to witness a significant rise with discovery of biosimilar drugs, rise in incidences of leukemia cases, and favorable reimbursement policies.

Also, increase in research and development activities by key market players and transition from branded drugs to biosimilars for neutropenia treatment is expected to drive the market growth during the forecast period. Moreover, robust drug pipeline for neutropenia treatment market is expected to provide lucrative opportunities for advanced treatment options. However, high cost of treatment of neutropenia and stringent rules and regulations for product approvals are anticipated to hamper the market growth during the forecast period. 
 

 

PURCHASE OPTIONS

Start reading instantly ,This title and over 12000 thousand more,available with Avenue Library, Subscription @ $699 T&C*

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,   
Int'l : +1-503-894-6022
( Europe )
+ 44-845-528-1300
Drop us an email at
help@alliedmarketresearch.com

FREQUENTLY ASKED QUESTIONS?
 

A. The total value of Neutropenia Treatment market was $ 12,602.5 million in 2019.

A. The forecast period in the report is from 2020-2027.

A. The market value of Neutropenia Treatment market in 2019 was $13,399 million.

A. The base year calculated is 2019 in the report.

A. Rise in R&D efforts by the key players to develop novel therpaies in the market is expected to drive the market growth during the forecast period.

A. The growth % of the Canada HER2-positive Metastatic Breast Cancer market is 5.4%.

A. Colony-stimulating factors segment holds the maximum market share.

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 

Download Sample

OR

Purchase Full Report of
Neutropenia Treatment Market

  • Online Only
  • $3,456  $3,110
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Data Pack
  • $3,840  $3,456
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $5,769  $4,904
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $6,450  $5,160
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise
    License/PDF

  • $8,995  $6,746
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Library Membership
  • $0.00
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Start reading instantly.
    This title and over 12,000+ are available on the Avenue Library. Subscription @ $699 T&C*.

    Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 

Featured Readings

 

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts